Protoporphyrin IX CAS 553-12-8

I. Photodynamic Therapy (PDT) and Photodynamic Diagnosis (PDD)

PPIX is one of the core photosensitizers in photodynamic therapy (PDT). Its mechanism of action is based on the production of reactive oxygen species (ROS) by the photosensitizer under specific wavelength light irradiation, which induces cell apoptosis or necrosis. PPIX has a selective enrichment property in tumor tissues, especially when its precursor 5-aminolevulinic acid (5-ALA) is externally administered. Tumor cells, due to their active metabolism, synthesize large amounts of PPIX, while normal cells accumulate less due to the regulatory effect of rate-limiting enzymes. This difference makes PPIX an ideal tool for tumor-targeted therapy.

In the treatment of skin diseases, PPIX-mediated PDT has been widely applied in the treatment of non-melanoma skin tumors (such as basal cell carcinoma, squamous cell carcinoma of the skin), actinic keratosis and condyloma acuminatum. For example, after topical application of 5-ALA to patients with basal cell carcinoma, PPIX accumulates in the tumor tissue. After activation by 405nm red light, it can selectively destroy cancer cells while preserving the normal tissue structure. Studies have shown that the sensitivity of PPIX-PDT for the treatment of basal cell carcinoma is 92.74%, and the specificity is 95.77%. In addition, the PPIX fluorescence diagnostic technique can achieve precise localization of skin lesions by detecting the red fluorescence (wavelength 630nm) emitted by the tumor tissue, guiding the delineation of the treatment area, significantly improving the efficacy and reducing recurrence.

In the field of vascular diseases, PPIX-PDT is used to treat vascular restenosis. Experiments have shown that PPIX can induce apoptosis of vascular smooth muscle cells, and the mechanism is related to the decrease in mitochondrial membrane potential. When the concentration of PPIX increased from 0.5 μg/mL to 20 μg/mL, the viability of smooth muscle cells decreased from 93% to 36%, and the apoptosis rate was positively correlated with the light dose. This discovery provides a theoretical basis for PDT treatment of atherosclerosis.

II. Multimodal Application in Cancer Treatment

PPIX demonstrates multimodal potential in cancer treatment. As a sonosensitizer, PPIX can be used in sonodynamic therapy (Sonodynamic Therapy, SDT), where ultrasound activates reactive oxygen species to induce tumor cell death. Animal experiments have shown that PPIX (5-25mg/kg) combined with ultrasound (5W/cm²) can significantly inhibit the growth of S180 xenograft tumors and prolong the survival time of mice. Its synergistic effect is superior to that of ultrasound or PPIX treatment alone.

In the treatment of bladder cancer, PPIX-PDT is administered locally through a urinary catheter, combined with intravesical light irradiation, to selectively eliminate superficial tumor cells. Clinical studies have shown that this therapy achieves a complete remission rate of 70%-80% for bladder carcinoma in situ, with mild side effects. Additionally, PPIX can be used in fluorescence-guided surgery. By real-time monitoring of the fluorescence signal of tumor tissue, it assists surgeons in precisely removing the lesion and reducing residual tumor cells.

III. Treatment of Liver Diseases

PPIX has dual mechanisms of action in the treatment of liver diseases. On one hand, as a precursor of hemoglobin, PPIX can participate in the synthesis of hemoglobin, thereby improving anemia conditions. On the other hand, its derivative, protoporphyrin sodium, has the functions of promoting liver cell respiration, regulating protein and sugar metabolism. Animal experiments have confirmed that protoporphyrin sodium can reduce the levels of aminotransferases in the carbon tetrachloride-induced liver injury model, improve amino acid metabolism, increase liver blood flow, and enhance the protein synthesis ability of liver cells. Clinical studies have shown that protoporphyrin sodium has certain therapeutic effects on acute hepatitis, chronic persistent hepatitis, chronic active hepatitis, and liver cirrhosis, and can significantly improve patient symptoms, reduce liver enlargement, and lower serum aminotransferase and jaundice indices.

IV. Basic Research and Drug Development

As a model compound, PPIX is used in basic research to explore the heme synthesis pathway, photodynamic reaction mechanism, and cell apoptosis regulatory network. For instance, studies have shown that PPIX can inhibit the interaction between tumor suppressor protein p53 and ubiquitin ligases MDM2/MDM4, stabilize the level of p53 protein, and induce p53-dependent apoptosis. This mechanism provides new ideas for the application of PPIX in the treatment of p53 wild-type tumors such as lymphoblastic leukemia.

Furthermore, as a radiation sensitizer, PPIX can still enhance ROS production and induce DNA damage under hypoxic conditions. This property makes it potentially valuable in the field of radiotherapy sensitization. Researchers are exploring the delivery of PPIX through nanocarriers to increase its enrichment efficiency in tumor tissues and reduce systemic toxicity.

V. Other Application Fields

PPIX also has certain applications in the agricultural field. As an inhibitor of protoporphyrinogen oxidase, a key target for herbicides of this type, the regulation of the metabolic pathway of PPIX can be utilized to develop new herbicides. Additionally, the fluorescence detection technology of PPIX is employed for the screening of lead poisoning and the diagnosis of iron deficiency anemia. By detecting the level of zinc protoporphyrin (ZPP) in red blood cells, the iron metabolism status in the body can be rapidly assessed.